IL326476A - Anti-cd203c antibody conjugates and uses thereof - Google Patents

Anti-cd203c antibody conjugates and uses thereof

Info

Publication number
IL326476A
IL326476A IL326476A IL32647626A IL326476A IL 326476 A IL326476 A IL 326476A IL 326476 A IL326476 A IL 326476A IL 32647626 A IL32647626 A IL 32647626A IL 326476 A IL326476 A IL 326476A
Authority
IL
Israel
Prior art keywords
antibody conjugates
cd203c antibody
cd203c
conjugates
antibody
Prior art date
Application number
IL326476A
Other languages
Hebrew (he)
Inventor
William James Jonathan Finlay
Orla Margaret Cunningham
Original Assignee
Granular Therapeutics Ltd
William James Jonathan Finlay
Orla Margaret Cunningham
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Granular Therapeutics Ltd, William James Jonathan Finlay, Orla Margaret Cunningham filed Critical Granular Therapeutics Ltd
Publication of IL326476A publication Critical patent/IL326476A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL326476A 2023-08-23 2024-08-23 Anti-cd203c antibody conjugates and uses thereof IL326476A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202363578246P 2023-08-23 2023-08-23
US202363595425P 2023-11-02 2023-11-02
PCT/EP2024/073759 WO2025040820A1 (en) 2023-08-23 2024-08-23 Anti-cd203c antibody conjugates and uses thereof

Publications (1)

Publication Number Publication Date
IL326476A true IL326476A (en) 2026-04-01

Family

ID=92632853

Family Applications (1)

Application Number Title Priority Date Filing Date
IL326476A IL326476A (en) 2023-08-23 2024-08-23 Anti-cd203c antibody conjugates and uses thereof

Country Status (5)

Country Link
CN (1) CN121712529A (en)
AU (1) AU2024329275A1 (en)
IL (1) IL326476A (en)
MX (1) MX2026001700A (en)
WO (1) WO2025040820A1 (en)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4975369A (en) 1988-04-21 1990-12-04 Eli Lilly And Company Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US6153655A (en) 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
PL215901B1 (en) 1999-04-15 2014-02-28 Bristol Myers Squibb Co Cyclic protein tyrosine kinase inhibitors
US7498298B2 (en) 2003-11-06 2009-03-03 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
WO2012113847A1 (en) 2011-02-25 2012-08-30 Lonza Ltd Branched linker for protein drug conjugates
WO2016115218A1 (en) * 2015-01-14 2016-07-21 The California Institute For Biomedical Research Antibody drug conjugates for the treatment of immune conditions
WO2019008555A1 (en) 2017-07-07 2019-01-10 Biocon Limited Polymorphic forms of dasatinib
AU2021386367A1 (en) * 2020-11-24 2023-06-22 Les Laboratoires Servier Bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
CN120787162A (en) * 2022-05-20 2025-10-14 诺华股份有限公司 Antibody-drug conjugates of antitumor compounds and methods of use thereof
JP2025526418A (en) * 2022-07-28 2025-08-13 グラニュラー セラピューティクス リミテッド Bispecific anti-c-kit and anti-cd203c antigen-binding molecules and uses thereof

Also Published As

Publication number Publication date
CN121712529A (en) 2026-03-20
WO2025040820A1 (en) 2025-02-27
AU2024329275A1 (en) 2026-03-19
MX2026001700A (en) 2026-03-02

Similar Documents

Publication Publication Date Title
IL304332A (en) Lrrc15 antibodies and conjugates thereof
GB2610467B (en) Anti-CLL1 antibody and application thereof
IL284974A (en) Anti-cd228 antibodies and antibody-drug conjugates
IL312566A (en) Antibody molecules and conjugates
GB202017058D0 (en) Antibodies and uses thereof
IL319931A (en) Anti-cd122 antibodies and uses thereof
EP4069297A4 (en) Anti-avb6 antibodies and antibody-drug conjugates
IL325624A (en) Conjugates and uses thereof
IL310778A (en) Sirp-alpha antibodies and conjugates
IL318296A (en) Anti-trop2 antibody and conjugate thereof
IL308812A (en) Neodegrader-anti-cd33 antibody conjugates
IL320586A (en) Anti-trem2 antibody and uses thereof
IL310333B1 (en) Conjugating reagents and conjugates thereof
IL316510A (en) Anti-b7h3 antibody and uses thereof
EP4437000A4 (en) Anti-trem2 antibody and uses thereof
EP4490199A4 (en) Modified antibodies and uses thereof
IL308485A (en) Antibody conjugate comprising anti-p-cadherin antibody and uses thereof
IL320972A (en) Anti-tfr1 antibodies and uses thereof
IL309048A (en) Anti-egfrviii antibody drug conjugates and uses thereof
IL326476A (en) Anti-cd203c antibody conjugates and uses thereof
GB202303531D0 (en) Antibodies and uses thereof
IL310247A (en) Nectin-4 antibodies and conjugates
CA3300188A1 (en) Anti-cd203c antibody conjugates and uses thereof
HK40087054A (en) Antibody molecule-drug conjugates and uses thereof
HK40113417A (en) Sirp-alpha antibodies and conjugates